Skip to main content

Table 3 Sources of heterogeneity in MMF vs placebo (or small dose of steroid)

From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review

Potential source of heterogeneity Studies (n) I2 P value
Placebo (or small dose steroid) 4 75% 0.007
Control    
Small dose of steroid 1 - -
Placebo 3 82% 0.003
Race    
Asian 2 62% 0.1
Non-Asian 2 0% 0.49
Duration of MMF use    
<18 moths 3 23% 0.27
≥18 months 1 - -
Mean Proteinuria    
<2 g 2 91% 0.0007
≥2 g 2 0% 0.89